Migraines
Chronic migraine affects roughly 3 million Americans, and the migraine-specific preventives approved for it all act on a single pathway, CGRP signaling. This brief sets out why Zhittya believes FGF-1 is worth investigating in the disease. The case is mechanistic rather than clinical. Chronic migraine is now understood as a neurovascular disorder expressed through the trigeminal nerve, and five independent bodies of published FGF-1 research, developed for entirely unrelated purposes, each land on a documented feature of the chronic state: impaired blood vessel repair, the trigeminal pain pathway, hypothalamic attack timing, inflammation in the lining of the brain, and energy, oxidative, and metabolic stress. There is no human data for FGF-1 in this indication and the brief claims none. What it argues is narrower: that the convergence is strong enough to justify asking the question, and that a molecule administered to more than 450 patients without a drug-related serious adverse event is one that can reasonably be studied in patients whom current preventives have not helped.